• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail
-

Number of compounders that recalled products

Dictionary: FDA is continuing surveillance and for-cause inspections of compounders, including compounders registered under section 503B of the Act, and FDA plans to take action, including enforcement actions, as appropriate to protect the public health. Since the fungal meningitis outbreak began, FDA has been conducting inspections of compounders for cause (in response to serious adverse event reports and reports of quality problems), and surveillance, to proactively identify pharmacies with deficient sterile compounding practices. Numerous recalls of sterile products have been conducted, and numerous compounders chose to stop sterile operations after FDA identified problems with their sterile compounding processes.

Information is current as of September 30, 2015.

Fiscal Year - 2015

Skip graphic and jump to text data

TimeTargetNumber
Oct 2014N/A1
Nov 2014N/A2
Dec 2014N/A1
Jan 2015N/A3
Feb 2015N/A1
Mar 2015N/A1
Apr 2015N/A2
May 2015N/A5
Jun 2015N/A2
Jul 2015N/A1
Aug 2015N/A3
Sep 2015N/A6

FY 2015 Total: 28

Footnotes

  • CDER began reporting on this measure in January 2014. CDER stopped reporting on this measure in September 2015.

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.

-
-